Abstract:BACKGROUND In the past 10 years, significant progress has been made in understanding the pathogenic chain of events that causes Alzheimer's disease (AD). According to the most widely accepted concept, the production and aggregation of β-amyloid (Aβ) peptides play a critical role in AD. As a result, therapeutic intervention with these processes is the focus of intense research. The Aβ peptide is cleaved by the α-secretase, β-secretase, and γ-secretase enzymes in a region near the pathogenic amyloid precursor protein (APP) and mutations occurring site. METHODS In the current review, a complete picture of the risk factors behind AD has been investigated. Mutations involved in AD progression have also been screened in various studies. RESULTS Most of the mutations in the amyloid precursor protein (APP) can lead to the accumulation of APP oligomers in the brain, leading to AD. Several point mutations in APP can cause familial AD (FAD), including the Swedish mutation (K>M670/671N>L) and the A673>V mutation. The pathogenic A673>V mutation and Swedish mutation (M670>K/N671>L) are present in the same region of amyloid precursor protein (APP). However, the A673>T mutation has been shown to confer protection against AD. CONCLUSION More investigations are needed from geographically distinct regions on mutations associated with AD development and applications of nanomedicines for better management of the disease burden in the future. Nanotechnology-produced metal nanoparticles (NPs) have gotten much attention because of their wide range of uses in the medicinal and agricultural industries. Nanomedicine containing potential phytochemicals, including GX-50 and curcumin conjugated with NPs, maybe a potential candidate for treating AD.

Nanozyme in Alzheimer's Disease diagnostics and therapy

Recent advances in nanoenzymes for Alzheimer's disease treatment

Application of nanotechnology for diagnosis of Alzheimer's disease

Functional nanoassemblies for the diagnosis and therapy of Alzheimer's diseases

Neuromodulation by nanozymes and ultrasound during Alzheimer's disease management

Emerging nanotechnology for Alzheimer's disease: From detection to treatment

Nanomaterials Toward the Treatment of Alzheimer’s Disease:Recent Advances and Future Trends

Recent Progress in Nanomedicine for the Diagnosis and Treatment of Alzheimer's Diseases

Nanomaterials that Aid in the Diagnosis and Treatment of Alzheimer's Disease, Resolving Blood-Brain Barrier Crossing Ability

Polyoxometalate-based nanozyme: Design of a multifunctional enzyme for multi-faceted treatment of Alzheimer’s disease

Research Progress of Novel Inorganic Nanomaterials in the Diagnosis and Treatment of Alzheimer’s Disease

Research Progress of Novel Inorganic Nanomaterials in the Diagnosis and Treatment of Alzheimer's Disease

Nanoparticle formulations in the diagnosis and therapy of Alzheimer's disease

Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges

Nanomedicine Strategies for Sustained, Controlled and Targeted Treatment of Alzheimer’s Disease

Versatile nanomaterials for Alzheimer's disease: Pathogenesis inspired disease-modifying therapy

Functional Nanomaterials for the Diagnosis of Alzheimer's Disease: Recent Progress and Future Perspectives

Potential of fluorescent nanoprobe in diagnosis and treatment of Alzheimer's disease

Alzheimer's Disease; Mechanism, Mutations, and Applications of Nano-Medicine.

Recent advances in nanotechnology for combating Alzheimer's disease

Nanomaterials for the treatment and diagnosis of Alzheimer's disease: An overview